---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-017078"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2021-12-30T23:59:59+00:00"
generated_at: "2026-06-27T21:38:17.600005+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Omeros closes $126M OMIDRIA sale to Rayner; deal valued >$1B including royalties

## Summary
- Received ~$126M cash at closing; retains accounts receivable.
- Eligible for $200M milestone if separate OMIDRIA payment secured for 4 consecutive years before 2025.
- US royalty: 50% of net sales until milestone/2025, then 30% through patent life (2032).
- Ex-US royalty: 15% of net sales on country-by-country basis.
- Transaction removes OMIDRIA revenue and costs from continuing ops; pro forma shows ongoing R&D and SG&A.

## SEC filing metadata
- accession: 0001558370-21-017078
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2021-12-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000155837021017078/0001558370-21-017078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000155837021017078/omer-20211223x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-017078
- JSON: https://secwatch.observer/filing/0001558370-21-017078.json
- Plain text: https://secwatch.observer/filing/0001558370-21-017078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.